The U.S. Food and Drug Administration (FDA) has approved a groundbreaking new treatment for children with sickle cell disease. On Wednesday (July 1), the FDA announced the approval of Casgevy, the first gene therapy for children as young as two years old with this condition. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, utilizes CRISPR/Cas9 technology to edit the patient’s own blood stem cells. It is administered as a one-time intravenous infusion, offering a potential functional cure for the disease.
The approval marks a significant milestone in the field of gene therapy, expanding the treatment’s eligibility from the previous age limit of 12 to now include younger patients. According to the FDA, Casgevy’s approval for children reflects the clinical urgency of early intervention to prevent irreversible damage caused by sickle cell disease, which can lead to severe pain and organ damage. BioPharm International reports that the therapy silences a gene repressor, reactivating fetal hemoglobin production to suppress disease pathology.
The FDA’s acting director of the Center for Biologics Evaluation and Research, Karim Mikhail, praised the therapy, stating it “gives these children a meaningful chance at a healthier future.” The treatment aims to eliminate the need for lifelong medication and frequent blood transfusions, providing a more sustainable solution for managing the disease. Respiratory Therapy highlights the therapy’s potential to reduce the risk of lasting organ damage through earlier intervention.
Casgevy’s approval follows the success of clinical trials that demonstrated its safety and efficacy in younger patients. The therapy is priced at approximately $2.2 million per treatment, and Vertex is working with hospitals to establish treatment centers across the U.S. to facilitate access. PSHP notes that Casgevy’s approval aligns it with Lyfgenia, another gene therapy for sickle cell disease, broadening treatment options for young patients.
Recent Comments